Immunome Inc. Contracts & Agreements
72 Contracts & Agreements
- Business Finance (16 contracts)
- Business Operations (4)
- Human Resources (34)
- Intellectual Property (6)
- Mergers & Acquisitions (1)
- Uncategorized (11)
- Amendment No. 2 to License Agreement, dated August 7, 2024, by and between Immunome, Inc. and Bristol-Myers Squibb Company (Filed With SEC on November 13, 2024)
- Stock Issuance Agreement dated October 25, 2024, by and between the Company and Zentalis Pharmaceuticals, Inc (Filed With SEC on October 29, 2024)
- Asset Purchase Agreement dated October 25, 2024, by and among the Company, Zentalis Pharmaceuticals, Inc. and Zeno Management, Inc (Filed With SEC on October 29, 2024)
- Employment Offer Letter dated June 17, 2024, by and between Immunome, Inc. and Phil Tsai (Filed With SEC on August 12, 2024)
- Sales Agreement, by and between Immunome, Inc. and TD Securities (USA) LLC, dated May 14, 2024 (Filed With SEC on May 14, 2024)
- Amended and Restated Employment Offer Terms dated November 30, 2023, by and between the Registrant and Sandra G. Stoneman (Filed With SEC on March 28, 2024)
- Amendment No. 1 to Executive Employment Agreement dated December 1, 2023, by and between the Registrant and Clay B. Siegall, Ph.D (Filed With SEC on March 28, 2024)
- Amended and Restated Employment Offer Terms dated December 21, 2023, by and between the Registrant and Bruce Turner, M.D., Ph.D (Filed With SEC on March 28, 2024)
- Amended and Restated Employment Offer Terms dated November 30, 2023, by and between the Registrant and Max Rosett (Filed With SEC on March 28, 2024)
- Amended and Restated Employment Offer Terms dated November 30, 2023, by and between the Registrant and Jack Higgins, Ph.D (Filed With SEC on March 28, 2024)
- Amended and Restated Employment Offer Terms dated November 30, 2023, by and between the Registrant and Robert Lechleider, M.D (Filed With SEC on March 28, 2024)
- Employment Offer dated November 30, 2023, by and between the Registrant and Philip Roberts (Filed With SEC on March 28, 2024)
- License Agreement, by and between the registrant and Zentalis Pharmaceuticals, Inc., dated January 5, 2024 (Filed With SEC on March 28, 2024)
- Separation Agreement effective October 2, 2023, by and between the Registrant and Dennis Giesing (Filed With SEC on March 28, 2024)
- Consulting Agreement dated October 2, 2023, by and between the Registrant and Dennis Giesing (Filed With SEC on March 28, 2024)
- Separation Agreement effective October 3, 2023, by and between the Registrant and Purnanand D. Sarma, Ph.D (Filed With SEC on March 28, 2024)
- Asset Purchase Agreement dated December 22, 2023, by and between the Registrant and Atreca, Inc (Filed With SEC on March 28, 2024)
- Employment Offer dated April 26, 2021, by and between the Registrant and Bob Lapetina (Filed With SEC on March 28, 2024)
- Employment Offer Letter dated February 7, 2024, by and between the Registrant and Kinney Horn (Filed With SEC on March 28, 2024)
- License Agreement dated November 29, 2017, by and between Immunome, Inc. (as assignee) and Bristol-Myers Squibb Company, as amended (Filed With SEC on March 26, 2024)
- Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, Cowen and Company, LLC, Leerink Partners LLC, and Guggenheim Securities, LLC, dated February 13, 2024 (Filed With SEC on February 14, 2024)
- Form of Ayala Pharmaceuticals, Inc. Support Agreement, dated February 5, 2024 (Filed With SEC on February 6, 2024)
- Asset Purchase Agreement dated February 5, 2024, by and between the Company and Ayala Pharmaceuticals, Inc (Filed With SEC on February 6, 2024)
- Consulting Agreement by and between the Company and Corleen Roche, effective as of January 2, 2024, as supplemented by Task Order #1 (Filed With SEC on December 29, 2023)
- Separation Agreement by and between the Company and Corleen Roche, dated December 22, 2023 (Filed With SEC on December 29, 2023)
- Third Amended and Restated Non-Employee Director Compensation Policy, effective October 27, 2023 (Filed With SEC on November 9, 2023)
- 2020 Immunome, Inc. Equity Incentive Plan, as amended (Filed With SEC on November 9, 2023)
- Form of Morphimmune, Inc. Indemnification Agreement (Filed With SEC on August 8, 2023)
- Forms of Restricted Stock Purchase Agreement, Stock Option Agreement and Early Exercise Stock Purchase Agreement under the Morphimmune, Inc. 2020 Equity Incentive Plan (Filed With SEC on August 8, 2023)
- Morphimmune, Inc. 2020 Equity Incentive Plan (Filed With SEC on August 8, 2023)
- Master License Agreement, by and between Morphimmune, Inc. and Purdue Research Foundation, dated as of January 19, 2021, as modified pursuant to that certain email by Max Rosett... (Filed With SEC on August 8, 2023)
- Master Sponsored Research Agreement, by and among Morphimmune, Inc., Purdue Research Foundation, and Purdue University, dated February 1, 2022, as amended by that certain... (Filed With SEC on August 8, 2023)
- Form of Morphimmune, Inc. Stockholder Support Agreement, dated June 29, 2023 (Filed With SEC on June 29, 2023)
- Employment Agreement, dated June 28, 2023, by and between Immunome, Inc. and Clay B. Siegall, Ph.D (Filed With SEC on June 29, 2023)
- Form of Subscription Agreement, dated June 29, 2023 (Filed With SEC on June 29, 2023)
- Form of Lock-Up Agreement, dated June 29, 2023 (Filed With SEC on June 29, 2023)
- Form of Immunome, Inc. Stockholder Support Agreement, dated June 29, 2023 (Filed With SEC on June 29, 2023)
- Agreement and Plan of Merger and Reorganization, dated June 29, 2023, by and among Immunome, Inc., Ibiza Merger Sub, Inc. and Morphimmune, Inc (Filed With SEC on June 29, 2023)
- Modification of Contract between the Company and the Department of Defense, United States of America, dated January 4, 2023 (Filed With SEC on March 16, 2023)
- Amended and Restated Employment Agreement of Matthew Robinson effective June 16, 2022 (Filed With SEC on March 16, 2023)
- Employment Agreement between the Company and Dennis Giesing effective April 7, 2021 (Filed With SEC on March 16, 2023)
- Letter Agreement by and between the registrant and the Whitehead Institute for Biomedical Research, dated November 17, 2022 (Filed With SEC on March 16, 2023)
- Amendment #2 to the License Agreement by and between the registrant and Arrayjet Limited, dated December 30, 2022 (Filed With SEC on March 16, 2023)
- Description of Securities (Filed With SEC on March 16, 2023)
- Letter to Holders of Series B Warrants to Purchase Shares of Common Stock (Filed With SEC on September 2, 2022)
- Second Amended and Restated Non-Employee Director Compensation Policy, effective as of June 15, 2022 (Filed With SEC on August 5, 2022)
- Modification of Contract between the Company and the Department of Defense, United States of America, dated March 18, 2022 (portions of this exhibit (indicated by asterisks) have... (Filed With SEC on May 12, 2022)
- Immunome, Inc. Annual Employee Bonus Plan (Filed With SEC on March 28, 2022)
- Description of Securities (Filed With SEC on March 28, 2022)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 15, 2021)
- Fourth Amendment to Second Amended and Restated Management Services Agreement, dated June 1, 2021, by and between the Company and Broadband Capital Partners LLC (Filed With SEC on August 16, 2021)
- Second Amended and Restated Employment Agreement, dated August 1, 2021, by and between the Company and Dr. Morin (Filed With SEC on August 5, 2021)
- Modification of Contract between the Company and the Department of Defense, United States of America, dated May 19, 2021 (portions of this exhibit (indicated by asterisks) have... (Filed With SEC on May 20, 2021)
- Engagement Letter, dated April 9, 2021, as amended on April 25, 2021, by and among Immunome, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on April 26, 2021)
- Form of Warrant (Filed With SEC on April 26, 2021)
- Securities Purchase Agreement, dated April 26, 2021, by and among Immunome, Inc. and the Purchasers signatory thereto (Filed With SEC on April 26, 2021)
- Employment Letter Agreement between the Company and Corleen M. Roche (Filed With SEC on April 20, 2021)
- Master Services Agreement, between the Company and Abzena (San Diego) Inc dated December 14, 2020 (Filed With SEC on March 25, 2021)
- Employment Agreement between the Company and Sandra G. Stoneman effective October 19, 2020 (Filed With SEC on March 25, 2021)
- Description of Securities (Filed With SEC on March 25, 2021)
- Separation Agreement and General Release between the Company and Richard Fitzgerald, dated December 1, 2020 (Filed With SEC on December 4, 2020)
- Second Amendment to License Agreement by and between the registrant and Thomas Jefferson University, dated July 28, 2020 (Filed With SEC on November 16, 2020)
- Amended and Restated Employment Agreement by and between the registrant and Michael J. Morin, dated September 23, 2020 (Filed With SEC on September 24, 2020)
- Form of Common Stock Certificate (Filed With SEC on September 24, 2020)
- Form of Amendment to 2020 Series A Preferred Stock Warrants (Filed With SEC on September 24, 2020)
- 2020 Equity Incentive Plan (Filed With SEC on September 24, 2020)
- Forms of Stock Option Grant Notice, Option Agreement, RSU Award Grant Notice and Notice of Exercise for the 2020 Equity Incentive Plan (Filed With SEC on September 24, 2020)
- 2020 Employee Stock Purchase Plan (Filed With SEC on September 24, 2020)
- Offer Letter Agreement by and between the registrant and Richard F. Fitzgerald, dated September 18, 2020 (Filed With SEC on September 24, 2020)
- Non-Employee Director Compensation Policy (Filed With SEC on September 24, 2020)
- Amended and Restated Employment Agreement by and between the registrant and Purnanand D. Sarma, dated September 23, 2020 (Filed With SEC on September 24, 2020)
- Form of Underwriting Agreement (Filed With SEC on September 9, 2020)
